http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2018000362-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
filingDate 2016-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e52fa3e1e64098f8db6de133fab381a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1afd152b14b048ee37e8672dfafd99d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_974fb7ac78d028e739a8f4dc574d5d85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e291dbecd0e8491c12bed9aeef0ec27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3e0dbdfec6d5d78e97854c91de62263
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ffa4aec34e1600d143a9056f9ee8d48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a0278fa98d3a3532855aa2754673a89
publicationDate 2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2018000362-A
titleOfInvention DERIVATIVES OF EXENDINA-4 AS SELECTIVE DUAL PEPTIDIC AGONISTS OF GLP-1 / GLUCAGON RECEPTORS.
abstract The present invention relates to dual agonists of GLP-1 / glucagon receptors and their modest use, for example in the treatment of disorders of metabolic syndrome, including diabetes and obesity, as well as for the reduction of excess intake of foods.
priorityDate 2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422601313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16157882

Total number of triples: 32.